ClinicalTrials.gg

Program

Ramucirumab

Also written as “IMC-1121B (ramucirumab)”, “Ramucirumab (IMC-1121B)” and “IMC-1121B”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Breast Neoplasms, led by 6 companies.

Furthest: phase 3, since Jun 20, 200858 company-led studies, 5 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly533 open or runningphase 3since Jun 20, 2008Aug 13, 2007May 2027phase 2 · NCT05999994
Arog Pharmaceuticals10 open or runningphase 1since Jun 14, 2017Jun 14, 2017none ahead
AstraZeneca11 open or runningphase 2since May 5, 2025May 5, 2025Feb 23, 2029phase 2 · NCT06996782
Innovent Biologics10 open or runningphase 3since Dec 3, 2020Dec 3, 2020none ahead
Merck11 open or runningphase 2since May 31, 2024May 31, 2024May 9, 2028phase 2 · NCT06445972
Sino Biopharmaceutical10 open or runningphase 1since Mar 24, 2023Mar 24, 2023none ahead

Also a collaborator on its studies: Daiichi Sankyo and parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 43 studies since Aug 13, 2007.

  1. Sep 25, 2015Phase 1 study in NeoplasmsEli Lilly · NCT02564198 · 29 enrolled · United States
  2. Mar 14, 2016Phase 2 study in Biliary Tract NeoplasmsEli Lilly · NCT02711553 · 309 enrolled · United States, Argentina, Australia and more
  3. May 31, 2016Phase 1 study in Carcinoma, Non-Small-Cell LungEli Lilly · NCT02789345 · 29 enrolled · United States, France, Korea, Republic of and more
  4. Jul 11, 2016Phase 2 study in Carcinoma, Non-Small-Cell LungEli Lilly · NCT02831491
  5. Sep 8, 2016Phase 3 study in Gastroesophageal Junction AdenocarcinomaEli Lilly · NCT02898077 · 440 enrolled · China, Malaysia, Philippines and more
  6. Jun 14, 2017Arog Pharmaceuticals's first study: phase 1 study in Esophagogastric AdenocarcinomaNew to Arog PharmaceuticalsArog Pharmaceuticals · NCT03193918 · 30 enrolled · United States
  7. Oct 29, 20192 phase 2 studiesEli Lilly · NCT04145700, NCT04145349
  8. Jul 30, 2020Phase 1 study in HealthyEli Lilly · NCT04495478 · 50 enrolled · United States
  9. Sep 16, 2020Phase 1 study in Advanced Solid TumorEli Lilly · NCT04557384 · 3 enrolled · United States, Japan
  10. Dec 3, 2020Innovent Biologics's first study: phase 3 study in Gastric AdenocarcinomaNew to Innovent BiologicsInnovent Biologics · NCT04675983 · 36 enrolled · China
  11. Mar 24, 2023Sino Biopharmaceutical's first study: phase 1 study in Stomach NeoplasmsNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT05800418 · 88 enrolled · China
  12. Aug 14, 2023Phase 2 study in NeoplasmsEli Lilly · NCT05999994 · 105 planned · United States, Australia, Belgium and more
  13. May 31, 2024Merck's first study: phase 2 study in Esophageal NeoplasmsNew to MerckMerck · NCT06445972 · 210 planned · United States, Brazil, Chile and more
  14. May 5, 2025AstraZeneca's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to AstraZenecaAstraZeneca · NCT06996782 · 152 planned · United States, Belgium, Brazil and more

Ahead

  1. May 2027Primary completion: phase 2 study in NeoplasmsEli Lilly · NCT05999994
  2. May 9, 2028Primary completion: phase 2 study in Esophageal NeoplasmsMerck · NCT06445972
  3. Feb 23, 2029Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT06996782

TargetBeta

KDR →read by rule
“A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity”NCIt, by rule
“Vascular endothelial growth factor receptor 2 inhibitor”ChEMBL 37, by rule

Other programs on KDR

ProgramCompanyFurthest phaseStudies
lenvatinibruleEisaiphase 481
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
cabozantinibruleExelixisphase 436
apatinibruleJiangsu HengRui Medicinephase 347
AxitinibrulePfizerphase 345
anlotinibruleSino Biopharmaceuticalphase 340
vorolanibruleBetta Pharmaceuticalsphase 324
zanzalintinibruleExelixisphase 317
chiauranibruleChipscreen Biosciencesphase 315
Aurora B/VEGFR/FGFR Inhibitor AL8326ruleadvenchen-laboratories-nanjing-ltdphase 38
AXL/FLT3/VEGFR2 Inhibitor KC1036rulebeijing-konruns-pharmaceutical-co-ltdphase 37

Studies

All 58 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06996782Carcinoma, Non-Small-Cell Lung · United States, Belgium, Brazil and more2RecruitingAstraZenecaFeb 23, 2029152
NCT06445972Esophageal Neoplasms · United States, Brazil, Chile and more2RecruitingMerckMay 9, 2028210
NCT05999994Neoplasms · United States, Australia, Belgium and more2RecruitingEli LillyMay 2027105
NCT05800418Stomach Neoplasms · China1CompletedSino BiopharmaceuticalFeb 18, 202088
NCT04675983Gastric Adenocarcinoma · China3TerminatedInnovent BiologicsFeb 12, 202336
NCT04557384Advanced Solid Tumor · United States, Japan1TerminatedEli LillyMay 25, 20213
NCT04495478Healthy · United States1CompletedEli LillyMay 9, 202150
NCT04145700Sarcoma, Synovial · United States, Australia, Belgium and more2TerminatedEli LillyFeb 23, 202323
NCT04145349Desmoplastic Small Round Cell Tumor · United States, Australia, Germany and more2CompletedEli LillyJun 14, 202430
NCT03193918Esophagogastric Adenocarcinoma · United States1CompletedArog PharmaceuticalsJul 15, 202030
NCT02898077Gastroesophageal Junction Adenocarcinoma · China, Malaysia, Philippines and more3CompletedEli LillyJun 30, 2020440
NCT02831491Carcinoma, Non-Small-Cell Lung2WithdrawnEli LillyJul 20170
NCT02789345Carcinoma, Non-Small-Cell Lung · United States, France, Korea, Republic of and more1CompletedEli LillyOct 19, 201729
NCT02711553Biliary Tract Neoplasms · United States, Argentina, Australia and more2Active, not recruitingEli LillyFeb 16, 2018309
NCT02564198Neoplasms · United States1CompletedEli LillyJul 16, 201929
NCT02539225Metastatic Gastric Adenocarcinoma · Japan, Korea, Republic of, Taiwan2CompletedEli LillyOct 25, 2017191
NCT02514551Stomach Neoplasms · United States, Belgium, Canada and more2CompletedEli LillyOct 27, 2017245
NCT02443883Stomach Neoplasms · United States, Argentina, Australia and more2CompletedEli LillyNov 18, 2016164
NCT02443324Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more1CompletedEli LillyAug 31, 2018175
NCT02435433Carcinoma, Hepatocellular · United States, Australia, Austria and more3CompletedEli LillyMar 15, 2018399
NCT02426125Carcinoma, Transitional Cell · United States, Australia, Belgium and more3CompletedEli LillyApr 21, 2017530
NCT02411448Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more3Active, not recruitingEli LillyJan 23, 2019545
NCT02314117Metastatic Gastric Adenocarcinoma · United States, Argentina, Belgium and more3CompletedEli LillyJan 17, 2017645
NCT02082210Liver Neoplasms · United States2CompletedEli LillyDec 5, 201797
NCT02079636Carcinoma, Non-Small-Cell Lung · United States, Spain1CompletedEli LillyMay 2, 2018142
NCT02069041Carcinoma, Hepatocellular · Taiwan1CompletedEli LillySep 20168
NCT01983878Stomach Neoplasms · Japan2CompletedEli LillyJan 201536
NCT01703091Non-small Cell Lung Cancer Metastatic · Japan2CompletedEli LillyDec 2014197
NCT01682135Solid Tumor · China1CompletedEli LillyMar 201528
NCT01634555Solid Tumors · United States2CompletedEli LillyAug 201329
NCT01567163Malignant Solid Tumor · United States2CompletedEli LillyDec 201222
NCT01515306Malignant Solid Tumor · United States2CompletedEli LillyMar 20, 201348
NCT01427933Breast Neoplasms · United States2CompletedEli LillySep 2013141
NCT01286818Colorectal Neoplasms · Japan1CompletedEli LillyFeb 20126
NCT01282463Urethral Neoplasms · United States, Canada2CompletedEli LillyFeb 2015148
NCT01256567Breast Neoplasms · Japan1CompletedEli LillyNov 20127
NCT01253525Adenocarcinoma · Japan1CompletedEli LillyOct 20116
NCT01246960Stomach Neoplasms · United States2CompletedEli LillySep 2013168
NCT01234402Breast Neoplasms · United States, Canada2CompletedEli LillyOct 2013153
NCT01183780Colorectal Neoplasms · United States, Argentina, Australia and more3CompletedEli LillyJul 17, 20141,072
NCT01170663Stomach Neoplasms · United States, Argentina, Australia and more3CompletedEli LillyJul 2013665
NCT01168973Carcinoma, Non-Small-Cell Lung · United States, Argentina, Austria and more3CompletedEli LillyDec 20131,253
NCT01160744Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more2CompletedEli LillyJan 2014280
NCT01140347Carcinoma, Hepatocellular · United States, Australia, Austria and more3CompletedEli LillyMar 2014565
NCT01111604Colonic Neoplasms · United States, Canada2CompletedEli LillyDec 2013158
NCT01017731Neoplasms · United States2CompletedEli LillyApr 201068
NCT01005355Advanced Solid Tumors · Japan1CompletedEli LillyFeb 201115
NCT00917384Stomach Neoplasms · United States, Argentina, Australia and more3CompletedEli LillyJul 2012355
NCT00862784Colorectal Neoplasms · Canada, Spain2CompletedEli LillyApr 201148
NCT00793975Neoplasms · United States1CompletedEli LillyJun 200937
NCT00786383Neoplasms · United States1CompletedEli LillyJan 200925
NCT00735696Carcinoma, Non-Small-Cell Lung · United States, United Kingdom2CompletedEli LillyOct 201141
NCT00721162Ovarian Neoplasms · United States, United Kingdom2CompletedEli LillyMay 201260
NCT00703326Breast Neoplasms · United States, Australia, Belgium and more3CompletedEli LillyMar 31, 20131,144
NCT00683475Prostatic Neoplasms · United States2CompletedEli LillySep 2011138
NCT00627042Carcinoma, Hepatocellular · United States2CompletedEli LillyMay 201142
NCT00533702Melanoma · United States2CompletedEli LillyMay 2011106
NCT00515697Carcinoma, Renal Cell · United States2CompletedEli LillyMay 201139

How it is read

Names in the registry

  • “Ramucirumab”, 36 entries
  • “IMC-1121B (ramucirumab)”, 4 entries
  • “Ramucirumab (IMC-1121B)”, 4 entries
  • “IMC-1121B”, 4 entries
  • “ramucirumab (IMC-1121B)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.